632 Eli Lilly and Company $LLY Shares Bought by Focus Financial Network Inc.

Focus Financial Network Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 9.0% during the third quarter, HoldingsChannel.com reports. The fund owned 7,646 shares of the company’s stock after buying an additional 632 shares during the quarter. Focus Financial Network Inc.’s holdings in Eli Lilly and Company were worth $8,847,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at $25,000. Basso Capital Management L.P. bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $30,000. Maseco LLP raised its stake in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the period. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $39,000. Finally, Aventus Investment Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 270.0% in the 1st quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after buying an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 over the last quarter. 0.14% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LLY. Bank of America increased their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research report on Friday, July 10th. JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $1,400.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Monday, September 28th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 23rd. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, August 26th. Finally, Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,313.43.

Eli Lilly and Company Stock Down 1.3%

Shares of NYSE LLY opened at $1,167.01 on Wednesday. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The stock has a market capitalization of $1.10 trillion, a PE ratio of 39.16, a P/E/G ratio of 1.52 and a beta of 0.46. Eli Lilly and Company has a one year low of $783.85 and a one year high of $1,292.65. The business’s fifty day moving average price is $1,176.60 and its 200-day moving average price is $1,102.08.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The company had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. During the same quarter last year, the firm posted $6.31 EPS. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 34.79 EPS for the current year.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts raised earnings estimates. Erste Group increased its FY2026 EPS forecast to $36.55 from $36.45 and its FY2027 estimate to $47.30 from $47.18, both above current consensus expectations. Erste Group raises Eli Lilly earnings estimates
• Positive Sentiment: Retatrutide remains the key long-term catalyst. Ahead of Lilly’s October 29 earnings report, investors are focused on whether the experimental triple-action obesity drug could become a growth driver larger than Zepbound. Lilly’s expected 2026 revenue of up to $87 billion and strong weight-loss-drug demand support the bullish case. Why the Retatrutide story matters
• Positive Sentiment: New oncology collaboration expands the pipeline. Prelude Therapeutics will test its experimental KAT6A degrader PRT13722 with Lilly’s Verzenio and Inluriyo in a Phase 1 breast-cancer trial, with enrollment expected in the fourth quarter of 2026. The program is early-stage but could create additional value if clinical results validate the combination. Prelude and Lilly clinical trial collaboration
• Neutral Sentiment: Upcoming earnings are a near-term focus. Investors will look for updates on diabetes and obesity-drug sales, full-year guidance, and retatrutide’s development timeline. Expectations for a potential revenue-outlook increase are supportive, but the results could also heighten volatility given Lilly’s elevated valuation. Lilly may raise revenue outlook
• Negative Sentiment: Clinical data contained a drawback. A combination regimen produced more weight loss than Zepbound alone, but discontinuation rates were substantially higher, raising questions about tolerability and commercial adoption of next-generation obesity treatments. Obesity-drug combination results
• Negative Sentiment: Valuation leaves less room for disappointment. Commentary highlights that LLY trades at a premium multiple near its highs, making the stock vulnerable to profit-taking or weaker-than-expected pipeline updates despite exceptional growth. Eli Lilly valuation review

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.